Home › Prostate Cancer › NCT06705803
Prostate Ablation Registry and Database for Information, Surveillance, and Evaluation (PARADISE)
Who can join
Ages 22 and older · Men
Full eligibility criteria
Inclusion Criteria: * Male sex * ≥22 years of age * Histologic diagnosis of prostate cancer * Scheduled to undergo or have already undergone ablation of the prostate as part of routine clinical care or any ongoing clinical trials * Prostate ablation performed with any of the following energy sources: cryotherapy, high-intensity focused ultrasound, irreversible electroporation, laser, microwave, radiofrequency ablation, or photodynamic therapy. Newer methods and instrumentation continue to be developed to ablate tissue, and these energy sources can be entered into the registry as clinical use begins Exclusion Criteria: * Under 21 Years of age.
About the study
Prostate cancer (PCa) is the most commonly diagnosed non-cutaneous cancer of men in the world. In 2023 alone, it is estimated that 288,300 US men will be diagnosed with prostate cancer and 34,700 will die from the disease despite the approval of multiple systemic agents. Due to advances in screening and imaging technology, PCa is now detected much earlier in its disease course. Prostate gland ablation for prostate cancer might provide the option for a "middle" ground between active surveillance (AS) and radical therapy by destroying prostate cancer in a minimally invasive or non-invasive fashion and thus limiting the morbidity. This treatment strategy is increasingly being offered to patients due to low morbidity but the data on long term oncologic efficacy and side effect profile is lacking for such a treatment strategy.
The purpose of this study is to create a database and prospective registry for data collection on patients with prostate cancer undergoing prostate ablation for the management of prostate cancer. Patients with biopsy-proven prostate cancer of any Gleason Grade will be entered into the registry as long as prostate ablation is used as the prostate cancer management modality. Historical data from 2017 to the present time will be added through chart review. Current and future patient data will be collected through chart review during the subject's clinical care. Only data available in the electronic medical record will be collected and no additional data will be collected for research purposes. No biospecimens will be collected, and there are no physical risks from study participation.
What is being tested
- Prostate Ablation (procedure)
Sponsor: University of Chicago · Participants: 3,000 · Started: Jun 21, 2024
Contact the study team
- Abhinav Sidana, MD · Phone: 773-834-5087
- Leila Yazdanbakhsh · Phone: 773-834-5087
Official record on ClinicalTrials.gov — NCT06705803
Locations in the U.S.
| Illinois | The University of Chicago, Hyde Park |
| Ohio | The University of Cinncinatti, Cincinnati |
Conditions
From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.